The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report

Table 1 Psychopharmacological history

Year	Medication	Dose	Duration	Notes
2013	Sertraline	50 mg	5 years	Recovery (primary treatment)
2018	Sertraline	200 mg	6 months	Partial response (primary treatment)
03/2019	Risperidone	2 mg	2 months	Stopped because of cognitive impairment (augmentation)
05/2019	Aripiprazole	5 mg	5 months	Stopped because of cognitive impairment (augmentation)
10/2019	Paroxetine	40 mg	6 months	No response (primary treatment, switched from Sertraline)
10/2019	Bupropion	300 mg	Ongoing	Partial response (combination)
01/2020	Olanzapine	5 mg	Ongoing	Partial response (combination)
01/2020	Lamotrigine	150 mg	Ongoing	Partial response (primary treatment)
06/2020	Venlafaxine	225 mg	Ongoing	Partial response (primary treatment)

ISSN: 1744-859X